Friday, August 05, 2016 10:58:57 AM
With the Zika news I agree that investors will look for a solid Zika-related stock. Not a scam stock, for sure.
As a LT holder of GOVX I have been attracted by their approach and prospects but disappointed so far by the results.
Maybe the lack of our stock pps rise some expected is due to the competition. How fast can GOVX move to compete? For example:
Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial
Phase I trial approved by US FDA and Health Canada
PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700). In addition to the previously announced US FDA approval for the conduct of the study, Health Canada’s Health Products and Food Branch has also approved this study, which will be conducted at clinical sites in Miami, Philadelphia, and Quebec City.
This phase I, open-label, dose-ranging study of 40 healthy adult volunteers is evaluating the safety, tolerability and immunogenicity of GLS-5700 administered with the CELLECTRA®-3P device, Inovio’s proprietary intradermal DNA delivery device. In preclinical testing, this synthetic vaccine induced robust antibody and T cell responses - the immune responses necessary to fight viral infections - in small and large animal models.
As a LT holder of GOVX I have been attracted by their approach and prospects but disappointed so far by the results.
Maybe the lack of our stock pps rise some expected is due to the competition. How fast can GOVX move to compete? For example:
Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial
Phase I trial approved by US FDA and Health Canada
PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700). In addition to the previously announced US FDA approval for the conduct of the study, Health Canada’s Health Products and Food Branch has also approved this study, which will be conducted at clinical sites in Miami, Philadelphia, and Quebec City.
This phase I, open-label, dose-ranging study of 40 healthy adult volunteers is evaluating the safety, tolerability and immunogenicity of GLS-5700 administered with the CELLECTRA®-3P device, Inovio’s proprietary intradermal DNA delivery device. In preclinical testing, this synthetic vaccine induced robust antibody and T cell responses - the immune responses necessary to fight viral infections - in small and large animal models.
Recent GOVX News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 09:15:01 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 08:55:19 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/18/2026 02:45:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:21:25 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/17/2026 03:33:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/26/2026 01:23:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 09:31:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2025 09:35:28 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 12/22/2025 11:50:46 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/12/2025 10:26:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:05:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 10:20:43 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/13/2025 10:19:09 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/13/2025 10:18:19 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/13/2025 10:17:20 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/13/2025 10:16:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:03:13 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/07/2025 09:43:56 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/17/2025 08:41:30 PM
- Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities • PR Newswire (US) • 07/16/2025 10:59:00 PM
- Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities • PR Newswire (US) • 07/16/2025 10:51:00 PM
